Reach Us +44 7482 877735


Update on Novel Therapies for Pancreatic Neuroendocrine Tumors: 2013

Neuroendocrine tumors of the pancreas (pNETs) are classified on the basis of their differentiation as well as the functionalstatus. Current treatment options for non resectable disease include everolimus, sunitinib, somatostatin analogs andchemotherapy. A number of trials with novel compounds and drug combinations were reported at the recent ASCO AnnualMeeting. Pasireotide is a novel somatostatin analog with broader affinity for the somatostatin receptors compared to thetraditional octreotide and lantreotide and it appears to be safe in patients with pNETs according to a phase I study (Abstract#e15126). The combination of octreotide with everolimus showed promising response rate and progression free survival ina phase II study (Abstract #4136). In another phase II study, the AKT inhibitor MK-2206 was well tolerated with moderateefficacy (Abstract #e15133). Last but not least, we discuss the updated data from a phase II study that used the combinationof temsirolimus with bevacizumab in patients with advanced pNETs (Abstract #4032).


Muhammad Wasif Saif, Kostas N Syrigos, Anastasios Dimou

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Flyer image
Abstracted/Indexed in
  • Index Copernicus
  • Academic Journals Database
  • Genamics JournalSeek
  • Academic Keys
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • British Library
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Emerging Sources Citation Index (ESCI)
  • EBSCO Host
  • MIAR
  • International Committee of Medical Journal Editors (ICMJE)
  • University of Zurich - UZH
  • University Grants Commission
  • SWB Online-Katalog
  • Scholarsteer
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs